Why the study?
Does high-dose tirilazad mesylate reduce mortality in women with aneurysmal subarachnoid hemorrhage?
Does high-dose tirilazad mesylate reduce mortality in women with aneurysmal subarachnoid hemorrhage?
High-dose tirilazad mesylate significantly reduces mortality in women with severe (Grade IV/V) aneurysmal subarachnoid hemorrhage, though it provides no overall mortality benefit across all neurological grades.
No takes yet. Share an insight, caveat, or question.
Supports tirilazad for severe (Grade IV/V) aneurysmal SAH in women; extends RCT evidence to high-risk subgroups without overall benefit.
Lanzino et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: